Dongwha Pharm.Co.Ltd (KO:000020) — Market Cap & Net Worth
Market Cap & Net Worth: Dongwha Pharm.Co.Ltd (000020)
Dongwha Pharm.Co.Ltd (KO:000020) has a market capitalization of $113.83 Million (₩167.97 Billion) as of May 2, 2026. Listed on the KO stock exchange, this Korea-based company holds position #18692 globally and #968 in its home market, demonstrating a 1.51% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dongwha Pharm.Co.Ltd's stock price ₩6060.00 by its total outstanding shares 27717930 (27.72 Million). Analyse Dongwha Pharm.Co.Ltd (000020) cash flow conversion to see how efficiently the company converts income to cash.
Dongwha Pharm.Co.Ltd Market Cap History: 2015 to 2026
Dongwha Pharm.Co.Ltd's market capitalization history from 2015 to 2026. Data shows change from $135.82 Million to $113.83 Million (-0.07% CAGR).
Dongwha Pharm.Co.Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Dongwha Pharm.Co.Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Dongwha Pharm.Co.Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.01x
Dongwha Pharm.Co.Ltd's market cap is 0.01 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $137.40 Million | $237.47 Billion | $26.25 Billion | 0.00x | 0.01x |
| 2017 | $167.67 Million | $258.88 Billion | $47.01 Billion | 0.00x | 0.00x |
| 2018 | $158.67 Million | $306.60 Billion | $10.07 Billion | 0.00x | 0.02x |
| 2019 | $147.10 Million | $307.15 Billion | $9.40 Billion | 0.00x | 0.02x |
| 2020 | $351.23 Million | $272.08 Billion | $28.51 Billion | 0.00x | 0.01x |
| 2021 | $264.25 Million | $293.02 Billion | $17.87 Billion | 0.00x | 0.01x |
| 2022 | $170.80 Million | $340.43 Billion | $20.38 Billion | 0.00x | 0.01x |
| 2023 | $192.91 Million | $361.11 Billion | $27.44 Billion | 0.00x | 0.01x |
| 2024 | $118.34 Million | $464.87 Billion | $5.56 Billion | 0.00x | 0.02x |
| 2025 | $117.40 Million | $496.39 Billion | $8.69 Billion | 0.00x | 0.01x |
Competitor Companies of 000020 by Market Capitalization
Companies near Dongwha Pharm.Co.Ltd in the global market cap rankings as of May 2, 2026.
Key companies related to Dongwha Pharm.Co.Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Dongwha Pharm.Co.Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Dongwha Pharm.Co.Ltd's market cap moved from $135.82 Million to $ 113.83 Million, with a yearly change of -0.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩113.83 Million | -3.04% |
| 2025 | ₩117.40 Million | -0.79% |
| 2024 | ₩118.34 Million | -38.66% |
| 2023 | ₩192.91 Million | +12.95% |
| 2022 | ₩170.80 Million | -35.36% |
| 2021 | ₩264.25 Million | -24.77% |
| 2020 | ₩351.23 Million | +138.77% |
| 2019 | ₩147.10 Million | -7.29% |
| 2018 | ₩158.67 Million | -5.37% |
| 2017 | ₩167.67 Million | +22.03% |
| 2016 | ₩137.40 Million | +1.16% |
| 2015 | ₩135.82 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Dongwha Pharm.Co.Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $113.83 Million USD |
| MoneyControl | $113.83 Million USD |
| MarketWatch | $113.83 Million USD |
| marketcap.company | $113.83 Million USD |
| Reuters | $113.83 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Dongwha Pharm.Co.Ltd
Dongwha Pharm.Co.,Ltd manufactures and sells pharmaceutical products in South Korea. It offers ethical products in the areas of alimentary system, antibiotic, cardiovascular/metabolic disease, NSAID/respiratory system, muscle relaxants/musculoskeletal system, nervous system, and dermatological/urinary system; OTC products in the areas of alimentary system, cold remedy, NSAID/respiratory system, d… Read more